- Home
- PBYI vs STTK Comparison
PBYI vs STTK Comparison
Compare PBYI & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- STTK
- Stock Information
- Founded
- PBYI 2010
- STTK 2016
- Country
- PBYI United States
- STTK United States
- Employees
- PBYI N/A
- STTK N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- PBYI Health Care
- STTK Health Care
- Exchange
- PBYI Nasdaq
- STTK Nasdaq
- Market Cap
- PBYI 176.1M
- STTK 173.6M
- IPO Year
- PBYI N/A
- STTK 2020
- Fundamental
- Price
- PBYI $2.59
- STTK $3.84
- Analyst Decision
- PBYI Strong Buy
- STTK Strong Buy
- Analyst Count
- PBYI 1
- STTK 3
- Target Price
- PBYI $7.00
- STTK $10.67
- AVG Volume (30 Days)
- PBYI 352.8K
- STTK 123.8K
- Earning Date
- PBYI 10-31-2024
- STTK 11-07-2024
- Dividend Yield
- PBYI N/A
- STTK N/A
- EPS Growth
- PBYI N/A
- STTK N/A
- EPS
- PBYI 0.18
- STTK N/A
- Revenue
- PBYI $219,143,000.00
- STTK $4,123,999.00
- Revenue This Year
- PBYI N/A
- STTK $164.45
- Revenue Next Year
- PBYI N/A
- STTK N/A
- P/E Ratio
- PBYI $13.95
- STTK N/A
- Revenue Growth
- PBYI N/A
- STTK 380.09
- 52 Week Low
- PBYI $2.13
- STTK $1.33
- 52 Week High
- PBYI $7.73
- STTK $11.76
- Technical
- Relative Strength Index (RSI)
- PBYI 45.60
- STTK 53.41
- Support Level
- PBYI $2.23
- STTK $3.63
- Resistance Level
- PBYI $2.42
- STTK $3.94
- Average True Range (ATR)
- PBYI 0.15
- STTK 0.22
- MACD
- PBYI 0.05
- STTK 0.06
- Stochastic Oscillator
- PBYI 76.60
- STTK 64.91
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.